The goal of this study is to find out whether the use of topical tranexamic acid (TXA) into the surgical wound will result in less post-operative pain, less pain killer use, and better post-operative use of the wrist in people undergoing surgery for a wrist fracture compared to not using topical TXA (placebo).
Patients undergoing open reduction internal fixation (Volar approach) for operative management of a distal radius fracture;
Aged 18 or older;
Provision of informed consent;
Cognitive ability and English-language skills required to complete outcome measures.
Revision surgery or any additional operative management of ipsilateral wrist injury
Distal radius fracture treated with a dorsal approach
Known history of lymphedema or lymph node dissection in the operative extremity
Known chronic pain conditions, fibromyalgia, or polymyalgia rheumatic
Parallel
Topical TRanexamic Acid
Drug10mL of 100mg/mL TXA will be administered into the surgical wound prior closure.
Placebo
Drug10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.
acute post-op pain
It will be assessed with VAS 0 to 10cm, with higher score indicating worse pain.
opioid use
Opioid use will be recorded on patients' medication diary
persistent pain
It will be assessed with VAS 0 to 10cm, with higher score indicating worse pain.
unscheduled hand-related procedures
clinic/emergency unit visits or any issue or events related to the condition that might lead participant to visit the emergency room, be seen by a doctor, or undergo any intervention more frequently than the usual visits
Patient reported function
will be assessed using the disabilities of the arm, shoulder and hand questionnaire (DASH) score 0 to 100, with higher score indicating more disability.
Click on the lead sponsor to view all of their trials.
